Damora Therapeutics Reports $31.2 Million Net Loss and Significant R&D Investment in Q2 2026

Damora Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $31.2 million for the three months ended June 30, 2026, compared to a loss of $3.4 million for the same period in 2025, marking an increase of 807%. For the six months ended June 30, 2026, the net loss was $59.0 million, up from $6.0 million in the prior year. The substantial increase in losses is attributed to heightened research and development expenses, which surged to $25.5 million in Q2 2026 from $1.5 million in Q2 2025, primarily due to costs associated with clinical trials and the Paramora warrant obligation.

The company’s total operating expenses for the second quarter of 2026 reached $35.0 million, a significant rise from $3.4 million in the same quarter of the previous year. This increase reflects the company's strategic focus on advancing its product candidates, particularly DMR-001, DMR-002, and DMR-003, which are aimed at treating hematological malignancies. The total cash and cash equivalents as of June 30, 2026, stood at $540.5 million, a notable increase from $257.6 million at the end of 2025, bolstered by recent financing activities including a public offering that generated approximately $295.5 million in net proceeds.

In terms of operational metrics, Damora has made significant strides in its clinical development pipeline. The company recently initiated a Phase 1/1b trial for DMR-001, targeting essential thrombocythemia and myelofibrosis patients. The trial is designed to rapidly identify a recommended dose and explore the drug's clinical potential across multiple patient populations. Additionally, Damora plans to submit regulatory filings for DMR-002 in the latter half of 2026 and for DMR-003 in 2027, indicating a proactive approach to expanding its product offerings.

The company has also undergone strategic organizational changes, including a name change from Galecto, Inc. to Damora Therapeutics, Inc., and a redomestication from Delaware to the Cayman Islands, effective July 16, 2026. These changes are part of a broader strategy to enhance operational efficiency and align with its growth objectives. Furthermore, Damora has increased its authorized shares from 300 million to 500 million, providing additional flexibility for future financing and growth initiatives.

Looking ahead, Damora Therapeutics anticipates continued investment in its research and development activities, with expectations of increased operating expenses as it advances its clinical trials. The company has indicated that it has sufficient resources to fund operations into the second half of 2029, although it will need to secure additional financing to support ongoing development efforts. The outlook remains contingent on the successful progression of its product candidates through clinical trials and eventual regulatory approvals, which are critical for generating future revenue.